US › Healthcare

LeonaBio, Inc. (LONA)

US · Healthcare · Biotechnology

$5.20-1.70%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-19.0M

EPS

$-0.80

EPS estimate

$-1.90

EPS came in at -0.80 against a street estimate of -1.90 — a beat of 57.9%.

Key statistics

Market cap

$60.6M

Forward P/E

0.0

P/B

1.65

Book value

$3.57

EPS (TTM)

$-23.01

52-week high

$14.21

52-week low

$2.21

50-day MA

$6.77

200-day MA

$7.64

Beta

2.12

Analyst view

Analysts rate LeonaBio, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $17.33.

Shareholding

Insiders

4.07%

Institutions

87.66%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	19.73%
Kalehua Capital Management LLC	8.36%
ADAR1 Capital Management LLC	8.25%
COMMODORE CAPITAL LP	4.93%
TCG Crossover Management, LLC	4.93%
NEA Management Company, LLC	4.93%
Spruce Street Capital LP	4.18%
Blackstone Inc	3.45%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LeonaBio, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.